PF-05212384 + PD-0325901

PF-05212384 + PD-0325901 is a combination of two investigational small molecule agents used in oncology research for advanced solid malignancies. - **PF-05212384** (also known as gedatolisib or PKI-587) is a potent, intravenous, pan-class I isoform inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) (inhibiting both TORC1 and TORC2 complexes). It modulates cell survival, proliferation, and growth pathways implicated in cancer. - **PD-0325901** is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which disrupts MAPK/ERK pathway signaling, key in cell proliferation and differentiation. This combination is designed to block both PI3K/mTOR and MAPK pathways, potentially providing synergistic antitumor activity, particularly in tumors with specific mutations such as KRAS. The combination has been studied in early-phase clinical trials, notably for advanced ovarian cancer, endometrial cancer, and other solid tumors with KRAS mutations, showing preliminary antitumor effects[1][3][4].

Other names

gedatolisib + PD-0325901